07:00 , Oct 7, 2013 |  BC Week In Review  |  Company News

Pierre Fabre, Neurolixis deal

Pierre Fabre's Pierre Fabre Medicament division granted Neurolixis exclusive, worldwide rights to develop and commercialize serotonergic compounds F15599 and befiradol. F15599 has completed one Phase I trial and befiradol has completed Phase II testing with...